The European Medicines Agency has awarded the status of a drug for rare diseases to the preparation for ovarian cancer treatment developed by Sotio. The company will thus be able to accelerate the drug’s testing, as it will not require as many patients for the clinical tests, Hospodářské noviny writes. Sotio, a member of PPF group, is the first Czech pharmaceutical company to be awarded such status. The development has not ended yet, though.
Source: CIANEWS, ihned.cz